Inventia Life Science, a Sidney, Australia-based world leader in advanced 3D cell cultures for research and clinical purposes, closed a US $25M Series B funding round.
The round was led by Blackbird Ventures with participation from Skip Capital.
The company intends to use the funds to market its RASTRUM™ 3D cell culture platform worldwide and grow its team from 36 to 150 employees by the end of 2024 and to develop a strong presence in the US.
Inventia has also announced the launch of its US operations with the appointment of Dwayne Dexter as its Director of US Sales. Dr. Dexter will be instrumental in growing the pharmaceutical and academic customer base and driving adoption of Inventia’s technology in the US and Canada. Currently, three of the leading US pharmaceutical companies are Inventia customers. Prior to joining Inventia, he served as the Director of US Operations at Mimetas, a US-based organ-on-a-chip provider.
Founded by CEO Dr. Julio Ribeiro Dr. Aidan O’Mahony, Dr. Cameron Ferris and Peter Arthur in 2013, Inventia is creating tools for advanced biomedical discovery. It builds printers and formulates bioinks that together allow human cells to be printed in 3 dimensional structures and help pioneers in the fields of cancer research, drug discovery and medicine to create human tissue for research and therapy purposes. Its RASTRUM™ platform creates 3D cell cultures which imitate real human tissue in terms of its structure and behaviour across a range of disease states.
The company is headquartered in Sydney, Australia.
FinSMEs
15/12/2021